| Analysis | Metabolite Name | Measured Value | Units | Treatment |
|---|---|---|---|---|
| ESI/Orbitrap Negative ion mode | Linoleic Acid (18:2) | 12.8 | Peak area | Diagnosis -No treatment |
| ESI/Orbitrap Negative ion mode | Linoleic Acid (18:2) | 27.3 | Peak area | Diagnosis -No treatment |
| ESI/Orbitrap Negative ion mode | Linoleic Acid (18:2) | 44.1 | Peak area | Post remission |
| ESI/Orbitrap Negative ion mode | Linoleic Acid (18:2) | 48.8 | Peak area | Diagnosis -No treatment |
| ESI/Orbitrap Negative ion mode | Linoleic Acid (18:2) | 52.7 | Peak area | Post remission |
| ESI/Orbitrap Negative ion mode | Linoleic Acid (18:2) | 60.1 | Peak area | Post remission |
| ESI/Orbitrap Negative ion mode | Linoleic Acid (18:2) | 60.3 | Peak area | Post remission |
| ESI/Orbitrap Negative ion mode | Linoleic Acid (18:2) | 61.6 | Peak area | Diagnosis -No treatment |
| ESI/Orbitrap Negative ion mode | Linoleic Acid (18:2) | 61.8 | Peak area | Diagnosis -No treatment |
| ESI/Orbitrap Negative ion mode | Linoleic Acid (18:2) | 65.6 | Peak area | Diagnosis -No treatment |
| ESI/Orbitrap Negative ion mode | Linoleic Acid (18:2) | 74.7 | Peak area | Post remission |
| ESI/Orbitrap Negative ion mode | Linoleic Acid (18:2) | 80.9 | Peak area | Diagnosis -No treatment |
| ESI/Orbitrap Negative ion mode | Linoleic Acid (18:2) | 85.9 | Peak area | Diagnosis -No treatment |
| ESI/Orbitrap Negative ion mode | Linoleic Acid (18:2) | 86.8 | Peak area | Diagnosis -No treatment |
| ESI/Orbitrap Negative ion mode | Linoleic Acid (18:2) | 93 | Peak area | Diagnosis -No treatment |
| ESI/Orbitrap Negative ion mode | Linoleic Acid (18:2) | 100 | Peak area | Diagnosis -No treatment |
| ESI/Orbitrap Negative ion mode | Linoleic Acid (18:2) | 114 | Peak area | Diagnosis -No treatment |
| ESI/Orbitrap Negative ion mode | Linoleic Acid (18:2) | 127 | Peak area | Diagnosis -No treatment |
| ESI/Orbitrap Negative ion mode | Linoleic Acid (18:2) | 149 | Peak area | Diagnosis -No treatment |
| ESI/Orbitrap Negative ion mode | Linoleic Acid (18:2) | 239 | Peak area | Post remission |
| ESI/Orbitrap Negative ion mode | Linoleic Acid (18:2) | 240 | Peak area | Diagnosis -No treatment |
| ESI/Orbitrap Negative ion mode | Linoleic Acid (18:2) | 295 | Peak area | Post remission |
| ESI/Orbitrap Negative ion mode | Linoleic Acid (18:2) | 375 | Peak area | Diagnosis -No treatment |
| ESI/Orbitrap Negative ion mode | Linoleic Acid (18:2) | 451 | Peak area | Diagnosis -No treatment |
| ESI/Orbitrap Negative ion mode | Linoleic Acid (18:2) | 466 | Peak area | Diagnosis -No treatment |
| ESI/Orbitrap Negative ion mode | Linoleic Acid (18:2) | 634 | Peak area | Diagnosis -No treatment |
| ESI/Orbitrap Negative ion mode | Linoleic Acid (18:2) | 877 | Peak area | Diagnosis -No treatment |
- UCSD Metabolomics Workbench, a resource sponsored by the Common Fund of the National Institutes of Health
|